[HTML][HTML] BRAF Alteration in Central and Peripheral Nervous System Tumors
K Srinivasa, KA Cross, S Dahiya - Frontiers in Oncology, 2020 - frontiersin.org
… observed in numerous primary central nervous system tumors as … -BRAF treated with an
analog of vemurafenib exhibit … cases of dramatic and sometimes-sustained response to BRAFi …
analog of vemurafenib exhibit … cases of dramatic and sometimes-sustained response to BRAFi …
Targeted therapy of BRAF V600E‐mutant histiocytic sarcoma: A case report and review of the literature.
B Branco, T Comont, L Ysebaert… - European Journal …, 2019 - search.ebscohost.com
… , we think that the remission observed is due to the BRAF inhibition. Optimal duration of …
Dramatic response of a BRAF V600E‐mutated primary CNS histiocytic sarcoma to vemurafenib. …
Dramatic response of a BRAF V600E‐mutated primary CNS histiocytic sarcoma to vemurafenib. …
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
…, C van den Bos, AGS van Halteren, H Histiocytic… - Blood Neoplasia, 2024 - Elsevier
… the diagnoses of histiocytic sarcoma (HS), Langerhans cell sarcoma 192 and interdigitating
dendritic cell sarcoma, … We also thank Roche for providing vemurafenib and/or cobimetinib. …
dendritic cell sarcoma, … We also thank Roche for providing vemurafenib and/or cobimetinib. …
A rare case of primary central nervous system histiocytic sarcoma harboring a novel ARHGAP45::BRAF fusion: a case report and literature review
L Zhang, G Zhang, H Zheng, B Jiang, Y Ju, Q Duan… - Brain Tumor …, 2024 - Springer
… published cases of primary central nervous system histiocytic sarcoma (PCNSHS) … It has
been demonstrated that vemurafenib treatment resulted in a 3-month response in a BRAF p.…
been demonstrated that vemurafenib treatment resulted in a 3-month response in a BRAF p.…
[HTML][HTML] Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma
V Shanmugam, GK Griffin, ED Jacobsen… - Modern Pathology, 2019 - Elsevier
… [27] treated a patient with isolated central nervous system histiocytic sarcoma harboring a
BRAF p.V600E mutation with vemurafenib who had a dramatic clinical and radiologic …
BRAF p.V600E mutation with vemurafenib who had a dramatic clinical and radiologic …
Histiocytic Tumors of the CNS
CR Lacruz, E Leonardo - Central Nervous System Tumors: Diagnostic …, 2024 - Springer
… Histiocytic sarcoma (HS) is a malignant hematopoietic … On imaging, HS mimics a malignant
primary CNS tumor, with … V600E mutations may respond to inhibitors (eg, vemurafenib)…
primary CNS tumor, with … V600E mutations may respond to inhibitors (eg, vemurafenib)…
Histiocytic tumours of the central
O Abla, J Picarsic - Oxford Textbook of Neurohaematology, 2024 - books.google.com
… response to the BRAF-V600E inhibitor vemurafenib was reported in a refractory case of
BRAF-V600E-mutated primary CNS-… for histiocytic sarcoma of the central nervous system. Leuk …
BRAF-V600E-mutated primary CNS-… for histiocytic sarcoma of the central nervous system. Leuk …
[HTML][HTML] A case of primary histiocytic sarcoma of the central nervous system
R Uno, M Kanzawa, K Tanaka, T Sasayama… - Human Pathology …, 2022 - Elsevier
… Histiocytic sarcoma (HS) is a highly malignant hematopoietic neoplasm that rarely arises in
the central nervous system (CNS)… Histiocytic sarcoma (HS) is a rare malignant hematopoietic …
the central nervous system (CNS)… Histiocytic sarcoma (HS) is a rare malignant hematopoietic …
[HTML][HTML] BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include …
J Picarsic, T Pysher, H Zhou, M Fluchel, T Pettit… - Acta Neuropathologica …, 2019 - Springer
… to the CNS-JXG diagnosis; CNS histiocytic sarcoma with … series to date of BRAF V600E
mutated pediatric JXG family … V600E mutation, including both primary CNS (ie, pleomorphic …
mutated pediatric JXG family … V600E mutation, including both primary CNS (ie, pleomorphic …
Treatment of Langerhans cell histiocytosis and histiocytic disorders: a focus on MAPK pathway inhibitors
AV Geerlinks, O Abla - Pediatric Drugs, 2023 - Springer
… responses to a BRAF-V600E inhibitor, vemurafenib, have been shown in a refractory
BRAF-V600E-mutated primary CNS … of disseminated or CNS histiocytic sarcoma remains very …
BRAF-V600E-mutated primary CNS … of disseminated or CNS histiocytic sarcoma remains very …